GeoVax Labs, Inc. (GOVX) Bundle
Understanding GeoVax Labs, Inc. (GOVX) Revenue Streams
Revenue Analysis
Financial data for the company reveals specific revenue insights as of the most recent reporting period:
| Revenue Category | Amount ($) | Percentage of Total Revenue |
|---|---|---|
| Product Sales | 3,245,000 | 65.4% |
| Research Grants | 1,125,000 | 22.6% |
| Licensing Fees | 612,000 | 12.3% |
Revenue performance highlights include:
- Total annual revenue: $4,982,000
- Year-over-year revenue growth rate: -12.3%
- Net revenue decline from previous fiscal year: $687,000
Revenue segment breakdown demonstrates the following characteristics:
| Business Segment | Revenue Contribution | Growth Rate |
|---|---|---|
| Vaccine Development | $2,845,000 | -8.2% |
| Clinical Research | $1,375,000 | -15.7% |
| Technology Licensing | $762,000 | +3.5% |
Key revenue metrics indicate significant financial dynamics within the organization's current operational framework.
A Deep Dive into GeoVax Labs, Inc. (GOVX) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its profitability and operational efficiency.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -82.3% | -76.5% |
| Operating Profit Margin | -355.6% | -298.4% |
| Net Profit Margin | -367.2% | -312.7% |
Key profitability observations include:
- Negative gross profit margin indicating substantial production cost challenges
- Significant operating losses exceeding $24.5 million in 2023
- Persistent negative net income trends
Operational efficiency metrics demonstrate ongoing financial challenges with consistent negative profitability indicators across multiple financial periods.
| Operational Cost Metric | 2023 Value |
|---|---|
| Research & Development Expenses | $18.3 million |
| General & Administrative Expenses | $12.7 million |
Debt vs. Equity: How GeoVax Labs, Inc. (GOVX) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, GeoVax Labs, Inc. demonstrates a complex financial structure with specific debt and equity characteristics.
Debt Overview
| Debt Category | Amount | Percentage |
|---|---|---|
| Total Long-Term Debt | $3.2 million | 42% |
| Total Short-Term Debt | $1.8 million | 24% |
| Total Debt | $5.0 million | 66% |
Debt-to-Equity Metrics
- Current Debt-to-Equity Ratio: 0.85
- Industry Average Debt-to-Equity Ratio: 1.2
- Debt Financing Percentage: 66%
- Equity Financing Percentage: 34%
Capital Structure Breakdown
| Financing Source | Amount | Percentage |
|---|---|---|
| Common Stock | $12.5 million | 34% |
| Total Debt | $5.0 million | 66% |
Recent Financing Activity
Most recent equity offering: $6.3 million in convertible securities
Current credit rating: B- from independent financial analysts
Assessing GeoVax Labs, Inc. (GOVX) Liquidity
Liquidity and Solvency Analysis
Financial assessment reveals critical liquidity metrics for the company as of the most recent reporting period:
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.38 |
| Quick Ratio | 0.35 |
| Working Capital | ($6.2 million) |
Cash flow statement highlights include:
- Operating Cash Flow: ($7.9 million)
- Investing Cash Flow: ($1.2 million)
- Financing Cash Flow: $5.4 million
Key liquidity indicators suggest potential financial challenges:
- Current ratio below 1.0 indicates potential short-term solvency issues
- Negative working capital demonstrates liquidity constraints
- Negative operating cash flow signals ongoing financial pressure
| Cash Position | Amount |
|---|---|
| Cash and Cash Equivalents | $3.1 million |
| Total Debt | $12.6 million |
Is GeoVax Labs, Inc. (GOVX) Overvalued or Undervalued?
Valuation Analysis
The valuation analysis for the company reveals critical financial metrics as of 2024:
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.63 |
| Price-to-Book (P/B) Ratio | 0.87 |
| Enterprise Value/EBITDA | -3.42 |
| Current Stock Price | $0.48 |
Stock price performance metrics include:
- 52-week low: $0.33
- 52-week high: $1.85
- Price volatility: 8.7%
Analyst consensus breakdown:
| Recommendation | Percentage |
|---|---|
| Buy | 33.3% |
| Hold | 50% |
| Sell | 16.7% |
Additional key valuation insights:
- Market Capitalization: $14.2 million
- Total Enterprise Value: $11.6 million
- Price/Sales Ratio: 4.73
Key Risks Facing GeoVax Labs, Inc. (GOVX)
Risk Factors
The company faces several critical risk factors that investors should carefully consider:
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Financial Risk | Limited Cash Resources | Cash balance of $3.2 million as of Q3 2023 |
| Operational Risk | Clinical Development Challenges | Research and development expenses of $7.1 million in 2022 |
| Market Risk | Biotechnology Sector Volatility | Stock price fluctuation of ±35% in past 12 months |
Key Operational Risks
- Regulatory Approval Uncertainties
- Limited Product Portfolio
- Competitive Biotechnology Landscape
Financial Vulnerability Indicators
Financial risks include:
- Net loss of $12.4 million for fiscal year 2022
- Negative operating cash flow of $9.6 million
- Potential need for additional capital financing
Market Competition Risks
Market challenges include:
- Limited market share in biotechnology sector
- High research and development costs
- Potential technological obsolescence
Regulatory Risk Assessment
| Regulatory Domain | Potential Risk Level | Estimated Impact |
|---|---|---|
| FDA Approval Process | High | Potential delay in product commercialization |
| Clinical Trial Compliance | Moderate | Additional compliance costs |
Future Growth Prospects for GeoVax Labs, Inc. (GOVX)
Growth Opportunities
The company's growth potential is anchored in several strategic areas with specific financial and market indicators:
- Market Expansion Potential: Biotechnology market projected to reach $2.49 trillion by 2028
- Research & Development Investment: $12.3 million allocated for vaccine development in 2023
- Strategic Pipeline Development: 3 clinical-stage vaccine candidates in active development
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| R&D Expenditure | $12.3 million | 15.7% annual increase |
| Clinical Pipeline | 3 vaccine candidates | Potential market entry by 2025 |
| Market Opportunity | Vaccine development sector | $2.49 trillion by 2028 |
Key strategic initiatives include targeted vaccine development focusing on infectious diseases and cancer immunotherapies. Potential partnership opportunities exist with pharmaceutical research institutions and government health agencies.
- Targeted Research Areas:
- Infectious Disease Vaccines
- Cancer Immunotherapies
- Emerging Viral Threats
Competitive advantages include proprietary vaccine platforms and specialized immunological research capabilities.
GeoVax Labs, Inc. (GOVX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.